Should ALNT Stock Be in Your Portfolio After a 143% Surge in a Year?

Allient's Q2 2026 revenue rose 10% year over year to $153.8 million, while adjusted EPS increased roughly 40% to $0.80 and adjusted EBITDA grew 18% to $23.7 million. Record orders of $201.3 million, up 49%, lifted backlog to $298 million and produced a 1.31 book-to-bill ratio, supporting revenue visibility into early 2027. Gross margin expanded 170bps to a record 34.9%, and fiscal 2026 EPS estimates rose 10.5% in 60 days to $2.73; ALNT shares have gained 143% over the past year.

Analysis

ALNT's key investable question is no longer demand visibility but incremental conversion: a high book-to-bill can sustain revenue growth into the next two reporting periods, while the operating model implies disproportionate EPS upside if mix and factory utilization persist. The risk is that a meaningful portion of the demand signal is tied to cyclical data-center or electrification programs with uneven release schedules; backlog supports timing, not necessarily quality or cancellation resistance. After a 143% rerating, further upside requires another leg of consensus EPS revisions and evidence that margin gains are structural rather than favorable mix.

Near term, ALNT should retain relative momentum versus CTS because its earnings revision cycle and operating leverage are stronger, but the valuation gap may now embed flawless execution. CTS is a cleaner second-order beneficiary if industrial/medical demand broadens, with less dependence on a single high-growth order cohort; FPS offers a higher-beta power-infrastructure read-through but requires verification of its own order conversion and margin profile. Over 6-18 months, deleveraging expands ALNT's acquisition capacity, yet using that capacity before organic margins are proven would dilute the simplification narrative.

The contrarian view is that the market may be annualizing a peak order quarter. A reversion of book-to-bill below 1.0, gross margin below roughly 34%, or any reduction in the next fiscal-year EPS trajectory would likely trigger sharp multiple compression in a relatively small industrial technology name, even if reported revenue remains healthy. Conversely, two consecutive quarters of double-digit organic growth with stable-to-higher margins would validate a higher-quality earnings base and make the current rally less speculative.

Key Decisions for Investors

• Do not chase ALNT at market after the extended move; establish a 1-2% starter long only on a 10-15% pullback or after the next earnings release confirms book-to-bill above 1.15 and gross margin at or above 34%. Target a 15-25% return over 3-6 months; exit if backlog conversion weakens or forward EPS estimates decline.
• Run a 3-6 month relative-value pair: long ALNT / short CTS in equal beta-adjusted dollars only while ALNT estimate revisions remain positive and CTS revisions lag. This isolates execution and backlog conversion; close if CTS receives material upward guidance or ALNT's order growth decelerates materially.
• For downside protection around the next earnings event, use ALNT put spreads rather than an outright short: buy a 5-10% out-of-the-money put and sell a 20-25% out-of-the-money put, 2-3 months out. The trade is justified by elevated expectation risk, not a base-case fundamental short.
• Set an alert for quarterly gross margin below 34%, book-to-bill below 1.0, or net leverage rising above 2.0x. Any of these would challenge the operating-leverage thesis and warrant reducing long exposure promptly.